Recent Updates
Recently added Catalysts
ANRO Positive Sentiment

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

Tuesday, November 3, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Alto Neuroscience (NYSE: ANRO) announced that its management team will participate in the Stifel 2026 Healthcare Conference. The company plans to hold a fireside chat and one-on-one meetings on November 11, 2026. This engagement allows the clinical-stage biopharmaceutical firm to discuss its precision medicines for neuropsychiatric disorders with investors.

Market Sentiment Analysis

POSITIVE FACTORS

  • Alto Neuroscience is actively engaging with investors.
  • Participation in notable conferences enhances visibility.
  • Management team will present at the Stifel 2026 Healthcare Conference.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+393%
120-day peak, hindsight
Typical move
10.5%
average across 2 past catalysts
Cash runway
~34 mo
Low dilution risk
Lead asset
ALTO-100
Phase 2 · Bipolar Disorder I or II With a Major Depressive Episode

Full Press Release Details

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company’s management team will participate in the following upcoming investor conferences:Stifel 2026 Healthcare Conference, November 10-12, 2026Format: Fireside chat and one-on-one meetingsPresentation Date & Time: Wednesday, November 11 at

Frequently Asked Questions

Which conferences will Alto Neuroscience attend?

Alto Neuroscience will attend the Stifel 2026 Healthcare Conference.

When is the Stifel 2026 Healthcare Conference?

The conference is scheduled for November 10-12, 2026.

What format will the presentations take?

The format includes a fireside chat and one-on-one meetings.

Who will represent Alto Neuroscience at the conferences?

Members of the company's management team will represent Alto.

ShareAdd on Google
Tags: ANRO Alto Neuroscience investor conferences Stifel 2026 neuropsychiatric disorders
Last updated: Nov 3, 2026

Biotech snapshot

Cash runway
$244M liquidity · $7M/mo burn
~34 mo
Low dilution risk
Lead asset
ALTO-100Phase 2
Bipolar Disorder I or II With a Major Depressive Episode →

Catalyst track record

+393%
best trade around ANRO's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for ANRO.

See every catalyst's timing & PoA →